Literature DB >> 32173832

Predictive factors for histological response to neo-adjuvant treatment in rectal cancers.

Dhouha Bacha, Ghofrane Talbi, Sana Ben Slama, Ahlem Lahmar, Lassad Gharbi, Saadia Bouraoui.   

Abstract

INTRODUCTION: The complete histological response represents the goal of neo-adjuvant treatment of locally advanced rectal cancer. This objective is a real challenge requiring the research of predictive factors for this response, from the perspective of targeted therapeutic strategies. The results of the various studies focused on these predictive factors are discordant. AIM: To seek a correlation between 7 prognostic factors tested in pre-therapy and the histological response to neo-adjuvant treatment.
METHODS: A retrospective study involving 44 patients with locally advanced rectal adenocarcinoma who received neo-adjuvant radiotherapy or radiochemotherapy. The 7 prognostic factors studied were clinical (age and sex), radiological (tumor size and parietal invasion) and histological (histological grade, vascular and nerve invasion) features. The complete histological response was defined by Bateman's tumor grade m-RCRG 1 and the absence of lymph node metastases.
RESULTS: A complete histological response was observed in 25% of cases (n = 11). In multivariate analysis, age> 60 years (OR: 1.14 and p = 0.028), male sex (OR: 21 and p = 0.045) and radiological wall invasion exceeding the subserosa (OR: 11 , 5 and p = 0.008) were significantly associated with the histological response. In contrast, none of the 3 histological factors tested were correlated with this response's intensity.
CONCLUSION: Age, gender, and pre-therapeutic parietal invasion could be used to select "good" and "poor" responders to neo-adjuvant treatment in locally advanced rectal cancers.

Entities:  

Year:  2019        PMID: 32173832

Source DB:  PubMed          Journal:  Tunis Med        ISSN: 0041-4131


  1 in total

1.  BMI May Be a Prognostic Factor for Local Advanced Rectal Cancer Patients Treated with Long-Term Neoadjuvant Chemoradiotherapy.

Authors:  Hengchang Liu; Ran Wei; Chunxiang Li; Zhixun Zhao; Xu Guan; Ming Yang; Zheng Liu; Xishan Wang; Zheng Jiang
Journal:  Cancer Manag Res       Date:  2020-10-20       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.